Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells
Skin biopsies show that CAR-T cell therapy can reverse tissue scarring in systemic sclerosis, a major shift from thinking fibrosis is permanent.
Skin biopsies from systemic sclerosis patients treated with CD19-CAR T cells (CASTLE study) showed structural skin regeneration — specifically recovery of dermal papillae, normalization of fibroblast phenotype, and vascular repair, demonstrated by cyclic in situ hybridization and imaging mass cytometry. This provides the first mechanistic evidence that B cell depletion via CAR-T can reverse fibrotic tissue remodeling in SSc, a disease where fibrosis was previously considered irreversible.
What the study was
- Study design
- Observational mechanistic study (clinical trial biopsy analysis)
- Population
- Patients with systemic sclerosis (SSc) treated with CD19-CAR T cells (CASTLE study + named patient use)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Nature Communications
Why it surfaced
Nat Commun publication from leading CAR-T/autoimmune group (Schett, Erlangen). First mechanistic evidence of structural tissue regeneration — including dermal papillae recovery — via CD19-CAR T cell therapy in SSc. Fibrosis reversal has been a longstanding barrier in SSc; this finding is paradigm-shifting if confirmed in larger cohorts. Observational design limits design_quality score; sample size not stated in abstract. Score capped at 8 (not 9-10) due to lack of randomized control arm.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.